Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis



Status:Recruiting
Conditions:Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:21 - Any
Updated:4/26/2018
Start Date:January 19, 2018
End Date:March 2020
Contact:Andrej Lyshchik, MD, PhD
Email:Andrej.Lyshchik@jefferson.edu
Phone:215-503-0587

Use our guide to learn which trials are right for you!

Contrast-Enhanced Ultrasound Evaluation of Focal Liver Lesions in Patients With Cirrhosis or Other Risk Factors for Developing HCC

This clinical trial studies how well contrast-enhanced ultrasound imaging works in diagnosing
liver cancer in patients with cirrhosis. Diagnostic procedures, such as contrast-enhanced
ultrasound imaging, may help find and diagnose liver cancer.

PRIMARY OBJECTIVES:

I. To evaluate the sensitivity, specificity, positive and negative predictive values of
contrast-enhanced ultrasound (CEUS) for diagnosis of hepatocellular carcinoma (HCC) in
patients at risk for HCC in a multicenter setting.

SECONDARY OBJECTIVES:

I. To validate CEUS Liver Imaging Reporting and Data System (LI-RADS) and determine the
prevalence of HCC in each CEUS LI-RADS category.

II. To evaluate inter-reader reliability of CEUS for HCC diagnosis. III. To evaluate
covariates that might limit diagnostic performance of CEUS for HCC diagnosis.

Inclusion Criteria:

- Capable of making informed decisions regarding his/her treatment

- Have known cirrhosis or other risk factors for HCC, based on American Association for
the Study of Liver Diseases (AASLD) and European Association for the Study of the
Liver (EASL) guidelines (applicable in each site jurisdictions)

- Patients with untreated focal liver observations on liver ultrasound or multiphase
contrast-enhanced CT or MRI performed as part of clinical standard of care within 4
weeks before patient enrollment.

OR

• Patients with untreated focal liver observations scheduled for follow-up multiphase
contrast-enhanced CT or MRI, biopsy or surgical excision as part of clinical standard of
care. CEUS should be performed within 4 weeks before or after follow-up imaging or within 4
weeks before biopsy or surgical excision.

Exclusion Criteria:

- Patients who are pregnant or lactating

- Patients with focal liver observations less than 5 mm or greater than 5 cm in size

- Patients with contraindications to CEUS

- Patients with contraindications to both CT and MRI

- Patients who are medically unstable, terminally ill, or whose clinical course is
unpredictable

- Liver nodule previously treated with trans-arterial or thermal ablation

- Patients who have received an investigational drug in the 30 days before CEUS, or will
receive one within 72 hour after their CEUS exam
We found this trial at
6
sites
2201 West End Ave
Nashville, Tennessee 37232
(615) 322-7311
Principal Investigator: Geoffrey Wilde, MD
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
2500 University Drive Northwest
Calgary, T2N 1N4
Principal Investigator: Stephanie Wilson, MD
?
mi
from
Calgary,
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
5501 Old York Road
Philadelphia, Pennsylvania 19141
215-456-7890
Principal Investigator: Shuchi Rodgers, MD
Phone: 215-456-3439
Albert Einstein Medical Center Einstein Healthcare Network is a private, not-for-profit organization with several major...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
San Diego, California 92093
Principal Investigator: Yuko Kono, MD
?
mi
from
San Diego, CA
Click here to add this to my saved trials
5300 Tallman Ave NW
Seattle, Washington 98122
(206) 782-2700
Principal Investigator: Lisa Finch, MD
Swedish Medical Center Since 1910, Swedish has been the region's hallmark for excellence in health...
?
mi
from
Seattle, WA
Click here to add this to my saved trials